Review



gene-modified 32d cell lines  (clea japan inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    clea japan inc gene-modified 32d cell lines
    iPAI-1 protects chronic myeloid leukemia cells from tyrosine kinase inhibitor treatment. (A) A representative flow cytometric profile for intracellular plasminogen activator inhibitor-1 (iPAI-1) expressions in PAI-1-overexpression (PAI-1 OE), PAI-1-knockdown (PAI-1 KD), or wild-type parental <t>32D</t> p210 cells (PAI-1 WT). (B) Representative flow cytometric profiles and percentage of Annexin V + /PI + population in PAI-1 OE, PAI-1 KD, or PAI-1 WT cells before imatinib (Pre-IM) and after imatinib (Post-IM) treatment in vitro (n=6). (C) Schema for in vivo experiments. (D) Representative flow cytometric profiles and percentages of leukemic cells in the bone marrow (BM) (n=7). Data represent means ± standard deviation. Statistical significance was determined by Mann-Whitney unpaired t -test. P <0.001, by a Kruskal-Wallis test. GFP: green fluorescent protein.
    Gene Modified 32d Cell Lines, supplied by clea japan inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gene-modified+32d+cell+lines/gene+modified+32d+cell+lines/pmc07849585-28-5-15
    Average 90 stars, based on 1 article reviews
    gene-modified 32d cell lines - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells"

    Article Title: Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells

    Journal: Haematologica

    doi: 10.3324/haematol.2019.230227

    iPAI-1 protects chronic myeloid leukemia cells from tyrosine kinase inhibitor treatment. (A) A representative flow cytometric profile for intracellular plasminogen activator inhibitor-1 (iPAI-1) expressions in PAI-1-overexpression (PAI-1 OE), PAI-1-knockdown (PAI-1 KD), or wild-type parental 32D p210 cells (PAI-1 WT). (B) Representative flow cytometric profiles and percentage of Annexin V + /PI + population in PAI-1 OE, PAI-1 KD, or PAI-1 WT cells before imatinib (Pre-IM) and after imatinib (Post-IM) treatment in vitro (n=6). (C) Schema for in vivo experiments. (D) Representative flow cytometric profiles and percentages of leukemic cells in the bone marrow (BM) (n=7). Data represent means ± standard deviation. Statistical significance was determined by Mann-Whitney unpaired t -test. P <0.001, by a Kruskal-Wallis test. GFP: green fluorescent protein.
    Figure Legend Snippet: iPAI-1 protects chronic myeloid leukemia cells from tyrosine kinase inhibitor treatment. (A) A representative flow cytometric profile for intracellular plasminogen activator inhibitor-1 (iPAI-1) expressions in PAI-1-overexpression (PAI-1 OE), PAI-1-knockdown (PAI-1 KD), or wild-type parental 32D p210 cells (PAI-1 WT). (B) Representative flow cytometric profiles and percentage of Annexin V + /PI + population in PAI-1 OE, PAI-1 KD, or PAI-1 WT cells before imatinib (Pre-IM) and after imatinib (Post-IM) treatment in vitro (n=6). (C) Schema for in vivo experiments. (D) Representative flow cytometric profiles and percentages of leukemic cells in the bone marrow (BM) (n=7). Data represent means ± standard deviation. Statistical significance was determined by Mann-Whitney unpaired t -test. P <0.001, by a Kruskal-Wallis test. GFP: green fluorescent protein.

    Techniques Used: Over Expression, In Vitro, In Vivo, Standard Deviation, MANN-WHITNEY



    Similar Products

    gene-modified 32d cell lines  (clea japan inc)
    90
    clea japan inc gene-modified 32d cell lines
    iPAI-1 protects chronic myeloid leukemia cells from tyrosine kinase inhibitor treatment. (A) A representative flow cytometric profile for intracellular plasminogen activator inhibitor-1 (iPAI-1) expressions in PAI-1-overexpression (PAI-1 OE), PAI-1-knockdown (PAI-1 KD), or wild-type parental <t>32D</t> p210 cells (PAI-1 WT). (B) Representative flow cytometric profiles and percentage of Annexin V + /PI + population in PAI-1 OE, PAI-1 KD, or PAI-1 WT cells before imatinib (Pre-IM) and after imatinib (Post-IM) treatment in vitro (n=6). (C) Schema for in vivo experiments. (D) Representative flow cytometric profiles and percentages of leukemic cells in the bone marrow (BM) (n=7). Data represent means ± standard deviation. Statistical significance was determined by Mann-Whitney unpaired t -test. P <0.001, by a Kruskal-Wallis test. GFP: green fluorescent protein.
    Gene Modified 32d Cell Lines, supplied by clea japan inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gene-modified+32d+cell+lines/gene+modified+32d+cell+lines/pmc07849585-28-5-15
    Average 90 stars, based on 1 article reviews
    gene-modified 32d cell lines - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    iPAI-1 protects chronic myeloid leukemia cells from tyrosine kinase inhibitor treatment. (A) A representative flow cytometric profile for intracellular plasminogen activator inhibitor-1 (iPAI-1) expressions in PAI-1-overexpression (PAI-1 OE), PAI-1-knockdown (PAI-1 KD), or wild-type parental 32D p210 cells (PAI-1 WT). (B) Representative flow cytometric profiles and percentage of Annexin V + /PI + population in PAI-1 OE, PAI-1 KD, or PAI-1 WT cells before imatinib (Pre-IM) and after imatinib (Post-IM) treatment in vitro (n=6). (C) Schema for in vivo experiments. (D) Representative flow cytometric profiles and percentages of leukemic cells in the bone marrow (BM) (n=7). Data represent means ± standard deviation. Statistical significance was determined by Mann-Whitney unpaired t -test. P <0.001, by a Kruskal-Wallis test. GFP: green fluorescent protein.

    Journal: Haematologica

    Article Title: Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells

    doi: 10.3324/haematol.2019.230227

    Figure Lengend Snippet: iPAI-1 protects chronic myeloid leukemia cells from tyrosine kinase inhibitor treatment. (A) A representative flow cytometric profile for intracellular plasminogen activator inhibitor-1 (iPAI-1) expressions in PAI-1-overexpression (PAI-1 OE), PAI-1-knockdown (PAI-1 KD), or wild-type parental 32D p210 cells (PAI-1 WT). (B) Representative flow cytometric profiles and percentage of Annexin V + /PI + population in PAI-1 OE, PAI-1 KD, or PAI-1 WT cells before imatinib (Pre-IM) and after imatinib (Post-IM) treatment in vitro (n=6). (C) Schema for in vivo experiments. (D) Representative flow cytometric profiles and percentages of leukemic cells in the bone marrow (BM) (n=7). Data represent means ± standard deviation. Statistical significance was determined by Mann-Whitney unpaired t -test. P <0.001, by a Kruskal-Wallis test. GFP: green fluorescent protein.

    Article Snippet: Another set of experiments, gene-modified 32D cell lines were also transplanted into non-irradiated C3H/HeNCrl mice (CLEA Japan).

    Techniques: Over Expression, In Vitro, In Vivo, Standard Deviation, MANN-WHITNEY